In a written response to a question in the Rajya Sabha, Jitendra Singh said Cadila Healthcare Ltd's DNA-based vaccine candidate is in phase three clinical trial
This picture has been used for representational purpose. Pic/AFP
Four Covid-19 vaccine candidates are at different stages of human trials while one, developed by Genique Life Sciences, is in the advanced pre-clinical stage, Union Science and Technology Minister Jitendra Singh said.
ADVERTISEMENT
In a written response to a question in the Rajya Sabha, Singh said Cadila Healthcare Ltd's DNA-based vaccine candidate is in phase three clinical trial. It has also submitted the interim data for emergency use authorisation. Biological E Ltd's vaccine candidate is also in phase three clinical trial. Bharat Biotech International Ltd's Adeno intranasal vaccine candidate is in phase three clinical trial, while Gennova Biopharmaceuticals Ltd's mRNA-vaccine candidate is in Phase one clinical trial.
The Gurugram-based Genique Life Sciences Pvt Ltd's vaccine candidate is in the advanced pre-clinical stage, Singh said. Currently, three vaccines --- Serum Institute of India's Covishield, Bharat Biotech's Covaxin and Russian vaccine Sputnik V are being administered in India.
Singh said 'Mission Covid Suraksha -- the Indian Covid-19 Vaccine Development Mission' was announced as part of the third stimulus package 'Atmanirbhar Bharat 3.0' for promoting research and development of Indian Covid-19 vaccines. "The mission is supporting the development of four vaccine candidates in the clinical stage of development and one vaccine candidate in advance pre-clinical stage of development. "The clinical development of vaccine candidates is being undertaken across the clinical trial sites situated pan-India," he added.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
